- Home
- TRAK vs CDTX Comparison
TRAK vs CDTX Comparison
Compare TRAK & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAK
- CDTX
- Stock Information
- Founded
- TRAK 1990
- CDTX 2012
- Country
- TRAK United States
- CDTX United States
- Employees
- TRAK N/A
- CDTX N/A
- Industry
- TRAK EDP Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRAK Technology
- CDTX Health Care
- Exchange
- TRAK Nasdaq
- CDTX Nasdaq
- Market Cap
- TRAK 374.5M
- CDTX 333.3M
- IPO Year
- TRAK 1998
- CDTX 2015
- Fundamental
- Price
- TRAK $19.10
- CDTX $49.33
- Analyst Decision
- TRAK
- CDTX Strong Buy
- Analyst Count
- TRAK 0
- CDTX 11
- Target Price
- TRAK N/A
- CDTX $49.44
- AVG Volume (30 Days)
- TRAK 45.3K
- CDTX 861.9K
- Earning Date
- TRAK 05-15-2025
- CDTX 08-12-2025
- Dividend Yield
- TRAK 0.38%
- CDTX N/A
- EPS Growth
- TRAK 21.41
- CDTX N/A
- EPS
- TRAK 0.34
- CDTX N/A
- Revenue
- TRAK $22,028,373.00
- CDTX $302,000.00
- Revenue This Year
- TRAK $15.18
- CDTX N/A
- Revenue Next Year
- TRAK $10.00
- CDTX N/A
- P/E Ratio
- TRAK $56.46
- CDTX N/A
- Revenue Growth
- TRAK 9.73
- CDTX N/A
- 52 Week Low
- TRAK $15.72
- CDTX $10.14
- 52 Week High
- TRAK $25.01
- CDTX $56.83
- Technical
- Relative Strength Index (RSI)
- TRAK 28.29
- CDTX 85.10
- Support Level
- TRAK $18.80
- CDTX $20.16
- Resistance Level
- TRAK $20.40
- CDTX $56.83
- Average True Range (ATR)
- TRAK 0.72
- CDTX 3.31
- MACD
- TRAK -0.21
- CDTX 2.68
- Stochastic Oscillator
- TRAK 8.75
- CDTX 79.55
About TRAK ReposiTrak Inc.
ReposiTrak Inc is a software as a service provider with extensive capabilities that gives their customers an easy, cost-efficient way to expand their services to their benefit. The company and its subsidiaries develop, market, and support proprietary software products. These products assist the management of business operations, which helps clients to make more informed decisions. The company also provides a cloud-based solution to remain in compliance with business records and regulatory requirements. The firm's services comprise implementation, business optimization, outsourcing, technical services, education, and application hosting.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.